the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
Published 5 days ago • 49 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:12
patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
1:22
long-term outcomes and toxicities of ibrutinib in cll
-
1:19:17
an insider's look: innovations in malignant hematology research
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
34:10
chronic lymphocytic leukemia (cll)
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:26
resonate: ibrutinib associated with favourable pfs and os in cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
6:37
brecadd regimen is superior in treating advanced hl: results from the hd21 trial
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment